Abstract: A method for assessing the presence and/or severity of fibrotic NASH in a subject, including measuring cytokeratin 18 (CK-18), aspartate aminotransferase (AST) and Homeostasis model assessment of insulin resistance (HOMA) in a sample of the subject. Also, a non-invasive accurate blood test for diagnosing fibrotic NASH including the determination of a score based on the combination of CK-18, AST and HOMA. Further, a method for treating fibrotic NASH and a method for monitoring treatment response.

Abstract: Method for providing a reliable non-invasive diagnostic test of the presence and/or severity of a disease, and associated software and expert system includes: a. collecting a diagnostic index, called Initial Index, preferably a score, b. calculating the Dispersion Index of the collected Initial Index, c. analyzing the reliability of each data by identifying if at least one data of index collected in step a) is an abnormal, inconsistent and/or a non-homogeneous data, or is responsible for a greater decrease in the Dispersion Index than that observed with other data, d. if a data is an abnormal, inconsistent and/or non-homogeneous data, or a data lowering a Dispersion Index, generating an Event Alert, e. if an Event Alert is generated, calculating new indexes, f. replacing the Initial Index including an abnormal, inconsistent and/or non-homogeneous data or a data affecting the Dispersion Index, with an Alternative, Estimated or a Mixed Index.

Abstract: The present invention relates to for treating for an individual identified as suffering from a liver lesion, preferably liver fibrosis or cirrhosis. The present invention thus relates to a method invention for implementing an adapted patient care for an individual suffering from a liver lesion, preferably liver fibrosis or cirrhosis, said method including the steps of (i) determining in the individual the presence and severity of a liver lesion, preferably liver fibrosis or cirrhosis, by carrying out at least one non-invasive test resulting in a value and positioning the at least one value in a class of a detailed classification; and (ii) implementing an adapted patient care for the individual depending on the severity of the liver lesion, preferably liver fibrosis or cirrhosis, as determined by the class of the detailed classification wherein the at least one value was positioned.

Abstract: This invention relates to method of diagnosing the presence and/or severity of a liver pathology and/or of monitoring the effectiveness of a curative treatment against a liver pathology in an individual, leading to a score, comprising the combination, of at least one marker from a blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, said physical method being further defined as elastometry, said combination being performed through a mathematical function.

Abstract: This invention relates to method of diagnosing the presence and/or severity of a liver pathology and/or of monitoring the effectiveness of a curative treatment against a liver pathology in an individual, leading to a score, comprising the combination, of at least one blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, said data being selected from the group consisting of medical imaging data and clinical measurements, said combination being performed through a mathematical function. This invention also relates to a method wherein the combination through a mathematical function, of at least one blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, is performed at least twice and the at least two resulting scores are combined in an algorithm based on the diagnostic reliable intervals.

Abstract: An in vitro prognostic method for assessing the risk of death or of liver-related event in a subject, includes: a) obtaining at least one, preferably 2, of the following variables from the subject: i. biomarkers measured in a sample from the subject; ii. clinical data; iii. binary markers; iv. blood test results; b) optionally obtaining at least one blood test result by univariate combination, preferably with a binary logistic regression, of the at least one variable obtained in step a), the blood test not being a Fibrotest, c) obtaining at least one physical data from medical imaging or clinical measurement, from elastometry, or Vibration Controlled Transient Elastography, and d) mathematically combining in a multivariate time-dependent model the variable obtained in step a) and/or the at least one blood test result obtained in step b); and the at least one physical data, obtained in step c) thereby obtaining a prognostic score.

Abstract: Method for providing a reliable non-invasive diagnostic test of the presence and/or severity of a disease, and associated software and expert system includes: a. collecting a diagnostic index, called Initial Index, preferably a score, b. calculating the Dispersion Index of the collected Initial Index, c. analyzing the reliability of each data by identifying if at least one data of index collected in step a) is an abnormal, inconsistent and/or a non-homogeneous data, or is responsible for a greater decrease in the Dispersion Index than that observed with other data, d. if a data is an abnormal, inconsistent and/or non-homogeneous data, or a data lowering a Dispersion Index, generating an Event Alert, e. if an Event Alert is generated, calculating new indexes, f. replacing the Initial Index including an abnormal, inconsistent and/or non-homogeneous data or a data affecting the Dispersion Index, with an Alternative, Estimated or a Mixed Index.

Abstract: The present invention relates to a non-invasive method for assessing the presence and/or severity of a lesion in an organ of an animal, including a human, said method comprising carrying out at least one non-invasive test resulting in a value, preferably a score result, and positioning the at least one value or score result in a class of a detailed classification, such as, for example, a detailed classification based on population percentiles, or on a reliable diagnostic interval (RDI), to be crossed with another RDI. The present invention also relates to a device, preferably a meter, carrying out the non-invasive method of the invention.

Abstract: This invention relates to method of diagnosing the presence and/or severity of a liver pathology and/or of monitoring the effectiveness of a curative treatment against a liver pathology in an individual, leading to a score, comprising the combination, of at least one blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, said data being selected from the group consisting of medical imaging data and clinical measurements, said combination being performed through a mathematical function. This invention also relates to a method wherein the combination through a mathematical function, of at least one blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, is performed at least twice and the at least two resulting scores are combined in an algorithm based on the diagnostic reliable intervals.